Literature DB >> 8435908

Calcipotriol. A new topical antipsoriatic.

K Kragballe1, L Iversen.   

Abstract

Calcipotriol is a synthetic vitamin D analogue. In vitro it can regulate cell differentiation and proliferation and suppress lymphocyte activities. These actions of calcipotriol at the cellular level are very similar to those of the natural hormone 1,25-(OH)2-D3. In contrast, the systemic effects on calcium and bone metabolism are at least 100 to 200 times less than those of 1,25-(OH)2-D3. Because of this unique pharmacologic profile, calcipotriol has been evaluated for the topical treatment of psoriasis. In well-designed and properly conducted studies involving more than 3000 patients, calcipotriol ointment, 50 micrograms/g, has been shown to be effective and safe for the short- and long-term treatment of psoriasis vulgaris. Calcipotriol ointment should be applied twice daily in amounts up to 100 g/week (Table 1). Used according to these guidelines, calcipotriol treatment does not affect calcium or bone metabolism. Calcipotriol is indicated for the treatment of plaque-type psoriasis vulgaris and has already been approved in several countries. It should be considered a first-line drug for the topical treatment of psoriasis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8435908

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  6 in total

1.  Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis.

Authors:  Mei Li; Pierre Hener; Zhikun Zhang; Shigeaki Kato; Daniel Metzger; Pierre Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-31       Impact factor: 11.205

Review 2.  Topical treatments for scalp psoriasis.

Authors:  Justin Gabriel Schlager; Stefanie Rosumeck; Ricardo Niklas Werner; Anja Jacobs; Jochen Schmitt; Christoph Schlager; Alexander Nast
Journal:  Cochrane Database Syst Rev       Date:  2016-02-26

3.  Safety and efficacy of calcipotriene plus betamethasone dipropionate topical suspension in the treatment of extensive scalp psoriasis in adolescents ages 12 to 17 years.

Authors:  Lawrence F Eichenfield; Cecilia Ganslandt; Merle Kurvits; Joel Schlessinger
Journal:  Pediatr Dermatol       Date:  2014-11-21       Impact factor: 1.588

4.  Extracellular CIRP Upregulates Proinflammatory Cytokine Expression via the NF-kappaB and ERK1/2 Signaling Pathways in Psoriatic Keratinocytes.

Authors:  Xiu Zhang; Shengbang Wang; Wei Wang; Liumei Song; Shuo Feng; Jingping Wang; Tong Kang; Peiwen Yang; Ning Wang; Pengju Yang; Ruimin Bai; Yongping Shao; Yan Zheng
Journal:  Mediators Inflamm       Date:  2022-09-06       Impact factor: 4.529

5.  Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study.

Authors:  John Koo; Stephen Tyring; William P Werschler; Suzanne Bruce; Martin Olesen; John Villumsen; Jerry Bagel
Journal:  J Dermatolog Treat       Date:  2015-10-07       Impact factor: 3.359

6.  A Novel Aerosol Foam Formulation of Calcipotriol and Betamethasone Has No Impact on HPA Axis and Calcium Homeostasis in Patients With Extensive Psoriasis Vulgaris.

Authors:  Victoria Taraska; Raj Tuppal; Martin Olesen; Claus Bang Pedersen; Kim Papp
Journal:  J Cutan Med Surg       Date:  2015-07-29       Impact factor: 2.092

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.